Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.
HEPATITIS C Drug
(SP - 30)
Infectious Disease Programs

SP-30: A NOVEL TREATMENT FOR HEPATITIS C
A small molecule Benzamide derivative indicated as a Hepatitis C (HCV) antiviral therapeutic.

SP-30 Capabilities:
  1. Inhibits HCV replication preventing Hepatitis C from entering healthy cells
  2. Presents a favorable safety profile (observed to have a selectivity index >32 in in-vitro studies)
  3. May be administered as a stand-alone therapeutic or in combination

SP-30 Profile: In two (2) National Institutes of Health (NIH) in-vitro studies, SP-30 showed a 96.3 % inhibition in preventing Hepatitis C from entering healthy cells compared to injectable Alpha-Interferon’s 97% inhibition with reported low efficacy and numerous side effects.

SP-30 Significance: HCV is characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. HCV is one of the most common types of viral hepatitis. It can lead to long-term, persistent infections, chronic liver disease, and in many cases, death. Liver failure due to HCV is the leading cause of liver transplants in the United States.


SP-30 Current Treatments: To date, there are no cures for HCV. Two forms of treatment are currently administered and a third class is being considered for approval into this $4 billion market (2004).
SP-01A HIV DRUG
Oral Entry
Inhibitor Drug
SP-10 HIV DRUG
Small Molecule
Antiviral Adjuvant
SP-30 HIV DRUG
Small Molecule
Antiviral Adjuvant

SP-30 Advantage: SP-30 appears to be the first true HCV antiviral therapeutic offered for treatment of individuals infected with HCV. In addition to its efficacy, SP-30 appears to have an extremely favorable safety profile, can be administered as a stand-alone or combination therapy, and may offer the convenience of oral dosing.

SP-30: Antiviral Properties
SP-30 has demonstrated promise in preclinical studies as an antiviral therapeutic in the treatment of Hepatitis C (HCV) as well as a therapeutic adjuvant in the treatment of HIV. SP-30 offers several distinctive competitive advantages as a potential adjuvant therapeutic in the treatment of HCV infected individuals. SP-30 is uniquely different from other inhibitors of viral replication in that it appears to condition the cell. This unique multiple target mechanism of action provides several advantages.

  1. In HCV infected individuals, SP-30 uses its unique mechanism to build a fence around the cell and prevent viral entry. Consequently, HCV is unable to replicate or mutate and is eventually eradicated by the immune system.
  2. Because SP-30's targets belong to the host cell and not to the virus itself, SP-30 may not be susceptible to the development of resistance.
  3. SP-30 does not appear to be contraindicated with any other currently approved ARV or HCV treatments.

Therefore, based on its favorable in-vitro inhibition data, Samaritan is developing a Phase I clinical study protocol for SP-30 as a potential adjuvant therapeutic in the treatment of HCV infected individuals.

SP-30: A NOVEL TREATMENT FOR HEPATITIS C
Hepatitis is a disease characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. Viral hepatitis refers to a set of at least six viruses that are known to cause hepatitis. Hepatitis C (HCV) is one of the most common types of viral hepatitis and it can lead to long-term, persistent infections, chronic liver disease, and in many cases, death. In contrast to most other types of hepatitis, more than 80% of HCV infections become chronic and lead to liver disease. Hepatitis C, in combination with hepatitis B, now accounts for 75% of all cases of liver disease around the world. Liver failure due to hepatitis C is the leading cause of liver transplants in the United States.

It is suspected that there are, at present, more than 4.5 million people in the United States that are infected with the hepatitis C virus (HCV), and more than 200 million around the world - making it one of the greatest public health threats faced in this century, and perhaps one of the greatest threats to be faced in the next century. A vaccine against hepatitis C may not be available for many years and there are already many times more people infected with HCV as have HIV. Although increased public awareness has led to a dramatic decrease in the number of new cases of acute HCV (from 230,000 a year in 1980 to 36,000 per year)i[i], without prompt intervention to treat infected populations and prevent the spread of disease, the death rate from hepatitis C will surpass that from AIDS.

In addition SP-30 demonstrated a very low toxicity profile in vitro.